Christer Nordstedt, Chairman of the board

Born 1962. Chairman since 2022.

MD and PhD in the field of pharmacology, Karolinska Institutet. Postgraduate at Rockefeller University in New York in the laboratory of the Nobel laureate Paul Greengard.

More than twenty years as a research leader in international executive positions at pharmaceutical companies such as Roche, Eli Lilly, AstraZeneca, Orion Corporations and most recently as global research manager for innovative drugs at TEVA. In these roles, he had extensive personnel responsibilities for large organizations with over a thousand employees and budgets covering several billion SEK.

Has been responsible for leading drug projects in areas such as oncology, neuroscience and inflammation. Responsibilities have included research from early discovery all the way through clinical phases to the market. Has also been responsible for in- and out-licensing of projects and molecules in various phases of its development.

Has been a board member of Orion Diagnostics and Fermion as well as non-profit organizations. For the past fifteen years has been living abroad, most recently in the United States.

Other assignments: Chairman Snevringe AB. CEO Oblique
Therapeutics AB and Vivesto AB.

Shareholdings: 101 000 shares.